2. Search Result
Search Result
Results for "

SARS

" in MedChemExpress (MCE) Product Catalog:

589

Inhibitors & Agonists

3

Screening Libraries

1

Fluorescent Dye

40

Peptides

35

Inhibitory Antibodies

49

Natural
Products

187

Recombinant Proteins

48

Isotope-Labeled Compounds

1

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P9803
    Anti-SARS-80R mAb

    SARS-80R; SARS Antibody-80R

    		 SARS-CoV Infection
    Anti-SARS-80R mAb (SARS-80R) is a human monoclonal IgG1 antibody produced in CHO cells. Anti-SARS-80R mAb can specifically bind to Spike (S1) protein to prevent SARS virus infection of susceptible cells .
    Anti-<em>SARS</em>-80R mAb
  • HY-151608
    SARS-CoV-2 Mpro-IN-3

    		SARS-CoV Infection
    SARS-CoV-2 Mpro-IN-3 is a potent M pro inhibitor with an IC50 value of ﹥5 μM. SARS-CoV-2 Mpro-IN-3 can be used in research of COVID-19 .
    <em>SARS</em>-CoV-2 Mpro-IN-3
  • HY-149955
    SARS-CoV-2-IN-38

    		SARS-CoV Infection
    SARS-CoV-2-IN-38 (compound 24) is a SARS-CoV-2 inhibitor with good oral bioavailability in mice (F%=39.75%) .
    <em>SARS</em>-CoV-2-IN-38
  • HY-150691
    SARS 3CLpro-IN-1

    		SARS-CoV Cancer
    SARS 3CLpro-IN-1 (Compound 3b) is a SARS 3CL protease inhibitor with an IC50 value of 95 μM, as a specific stereo isomer of the octahydroisochromene scaffold, directs the P1 site imidazole .
    <em>SARS</em> 3CLpro-IN-1
  • HY-155308
    SARS-CoV-2-IN-61

    		SARS-CoV Infection
    SARS-CoV-2-IN-61 (compound 8i) is a SARS CoV-2 PLpro inhibitor with an IC50 of 16 µM. SARS-CoV-2-IN-61 has antiviral activities .
    <em>SARS</em>-CoV-2-IN-61
  • HY-P9807
    Anti-SARS-CoV-2 Spike mAb (CR3022)

    SARS-CR3022; SARS-CoV-2 Antibody-CR3022

    		 SARS-CoV Infection Inflammation/Immunology
    Anti-SARS-CoV-2 Spike mAb (CR3022) is a a CHO cell derived human monoclonal IgG1 antibody. It binds to both S1 domain of SARS-CoV/SARS-CoV-2 Spike protein .
    Anti-<em>SARS</em>-CoV-2 Spike mAb (CR3022)
  • HY-150783
    SARS-CoV-2-IN-24

    		SARS-CoV Infection
    SARS-CoV-2-IN-24 (compound 7) is a potent papain-like protease (PL pro) inhibitor. SARS-CoV-2-IN-24 induces conformational changes in SARS-COV-2 papain-like protease, inhibiting SARS-CoV-2 replication. SARS-CoV-2-IN-24 can be used for SARS-CoV-2 research .
    <em>SARS</em>-CoV-2-IN-24
  • HY-155119
    SARS-CoV-2-IN-54

    		SARS-CoV Infection
    SARS-CoV-2-IN-54 (Compound 2) is a SARS-CoV-2 inhibitor. SARS-CoV-2-IN-54 has antiviral activity. SARS-CoV-2-IN-54 inhibits SARS-CoV-2 in Vero E6 cells, with an IC50 of 21.4 μM .
    <em>SARS</em>-CoV-2-IN-54
  • HY-155121
    SARS-CoV-2-IN-56

    		SARS-CoV Infection
    SARS-CoV-2-IN-56 (Compound 63) is a SARS-CoV-2 inhibitor. SARS-CoV-2-IN-56 has antiviral activity. SARS-CoV-2-IN-56 inhibits SARS-CoV-2 in Vero E6 cells, with an IC50 of 0.7 μM .
    <em>SARS</em>-CoV-2-IN-56
  • HY-143467
    SARS-CoV-IN-4

    		SARS-CoV Infection
    SARS-CoV-IN-4 (compound 13) is a potent and specific inhibitor of SARS-CoV nsp14 N7-methyltransferase, with an IC50 of 0.6 μM (SARS-CoV nsp14) .
    <em>SARS</em>-CoV-IN-4
  • HY-149954
    SARS-CoV-2-IN-39

    		SARS-CoV Infection
    SARS-CoV-2-IN-39 (compound 21) is a SARS-CoV-2 inhibitor with an EC50 of 1 μM. SARS-CoV-2-IN-39 against SARS-CoV-2 by inhibiting of SKP2 protein and stabilizing BECN1 .
    <em>SARS</em>-CoV-2-IN-39
  • HY-136606
    SARS-CoV MPro-IN-1

    		SARS-CoV Infection
    SARS-CoV MPro-IN-1 is a SARS-CoV-2 3CLpro covalent inhibitor, with an IC50 of 40 nM. SARS-CoV MPro-IN-1 shows good anti-SARS-CoV-2-infection activity in cell culture with an EC50 of 0.33 μM. SARS-CoV MPro-IN-1 has the potential for COVID-19 research .
    <em>SARS</em>-CoV MPro-IN-1
  • HY-156008
    SARS-CoV-2-IN-58

    		SARS-CoV Virus Protease Infection
    SARS-CoV-2-IN-58 (Compound 21H) is an antiviral agent against SARS-CoV-2 (EC50: 18 μM). SARS-CoV-2-IN-58 inhibits SARS-CoV-2 M pro with an IC50 of 0.35 μM .
    <em>SARS</em>-CoV-2-IN-58
  • HY-151988
    SARS-CoV-2-IN-36

    		SARS-CoV Infection
    SARS-CoV-2-IN-36 is a potent SARS-CoV-2 Mpro (SARS-CoV) inhibitor with an IC50 of 2.37 μM and a Kd of 1.19 μM in enzymatic assays. SARS-CoV-2-IN-36 shows antiviral activity against UC-1074, RG2674, and NVDBB-2220 SARS-CoV-2 variants in Vero cells .
    <em>SARS</em>-CoV-2-IN-36
  • HY-155015
    SARS-CoV-2-IN-45

    		SARS-CoV Infection
    SARS-CoV-2-IN-45 (Compound 8p) is a SARS-CoV-2 inhibitor. SARS-CoV-2-IN-45 inhibits SARS-CoV-2 replication in Calu-3 cell with an EC50 of 0.5 μM, and has no evident cytotoxic effect .
    <em>SARS</em>-CoV-2-IN-45
  • HY-162154
    SARS-CoV-2-IN-75

    		SARS-CoV Infection
    SARS-CoV-2-IN-75 (compound 13) is a SARS-CoV-2 inhibitor based on chloroacetamide inhibition. SARS-CoV-2-IN-75 inhibits cellular SARS-CoV-2 replication with an EC68 (half-log reduction in viral titer) of 3 μM .
    <em>SARS</em>-CoV-2-IN-75
  • HY-135860
    SARS-CoV-2-IN-1

    		Virus Protease SARS-CoV Infection
    SARS-CoV-2-IN-1 is a potent Mpro inhibitor. SARS-CoV-2-IN-1 inhibits the purified recombinant SARS-CoV-2 Mpro, SARS-CoV Mpro and MERS-CoV Mpro with IC50s of 0.67, 0.90 and 0.58 μM, respectively .
    <em>SARS</em>-CoV-2-IN-1
  • HY-135858
    SARS-CoV-IN-3
    1 Publications Verification

    		 SARS-CoV Parasite HIV Infection
    SARS-CoV-IN-3 is an effective inhibitor of SARS-CoV replication. SARS-CoV-IN-3 shows anti-Coronavirus activity with an EC50 of 3.6 μM in Vero cells. SARS-CoV-IN-3 inhibits the 3D7 and W2 strains of P. falciparum with IC50s of 11.7 and 20.4 nM; and IC90s of 29.19 and 56 nM; respectively. SARS-CoV-IN-3 reduces HIV-1-induced cytopathic effect with an EC50 of 10 μM in MT-4 cells .
    <em>SARS</em>-CoV-IN-3
  • HY-162177
    SARS-CoV-2-IN-78

    		SARS-CoV Infection
    SARS-CoV-2-IN-78 (compound 3) is an inhibitor for nsp14 of SARS-Cov-2. SARS-CoV-2-IN-78 reveals antiviral activity as N7 methyltrabsferase .
    <em>SARS</em>-CoV-2-IN-78
  • HY-149304
    SARS-CoV-2-IN-40

    		SARS-CoV Infection
    SARS-CoV-2-IN-40 (Compound 19) is a SARS-CoV-2 inhibitor. SARS-CoV-2-IN-40 inhibits SARS-CoV-2 BA.1 and BA.5 variant infection of Calu3 lung cells, with IC50s of 100 nM and 160 nM respectively .
    <em>SARS</em>-CoV-2-IN-40
  • HY-146379
    SARS-CoV-2-IN-19

    		SARS-CoV Infection
    SARS-CoV-2-IN-19 (Compound 6g) is a potent inhibitor of SARS-CoV-2 with an EC50 of 8.8 μM. SARS-CoV-2-IN-19 shows potent activity against SARS-CoV-2 helicase (nsp13), a highly conserved enzyme, highlighting a potentiality against emerging HCoVs outbreaks. SARS-CoV-2-IN-19 has the potential for the research of infection diseases .
    <em>SARS</em>-CoV-2-IN-19
  • HY-143417
    SARS-CoV-2-IN-16

    		SARS-CoV Infection
    SARS-CoV-2-IN-16 (Compound 12) is a potent SARS-CoV-2 nucleocapsid protein (NPro) inhibitor. SARS-CoV-2-IN-16 exhibits potent anti-viral activity with the EC50 of 3.69 μM. SARS-CoV-2-IN-16 binds to NPro with the low KD value of 7.82 μM, suggesting that SARS-CoV-2-IN-16 is a potent NPro ligand .
    <em>SARS</em>-CoV-2-IN-16
  • HY-143418
    SARS-CoV-2-IN-17

    		SARS-CoV Infection
    SARS-CoV-2-IN-17 (Compound 16) is a potent SARS-CoV-2 nucleocapsid protein (NPro) inhibitor. SARS-CoV-2-IN-17 exhibits potent anti-viral activity with the EC50 of 2.18 μM. SARS-CoV-2-IN-17 binds to NPro with the low KD value of 7.82 μM, suggesting that SARS-CoV-2-IN-17 is a potent NPro ligand .
    <em>SARS</em>-CoV-2-IN-17
  • HY-135855
    SARS-CoV-IN-1
    1 Publications Verification

    		 SARS-CoV Parasite Infection
    SARS-CoV-IN-1 is an effective inhibitor of SARS-CoV replication. SARS-CoV-IN-1 shows anti-Coronavirus activity with an EC50 of 4.9 μM in Vero cells. SARS-CoV-IN-1 inhibits the 3D7 and W2 strains of P. falciparum with IC50s of 15.4 and 133.2 nM; and IC90s of 25.7 and 459.1 nM; respectively. Antimalarial and antiviral activities .
    <em>SARS</em>-CoV-IN-1
  • HY-157022
    SARS-CoV-2-IN-67

    		SARS-CoV Infection
    SARS-CoV-2-IN-67 (Compound 16), a vitamin K derivatives, has anti-SARS-CoV-2 activity (EC50: 64.8 μM in VeroE6/TMPRSS2 cells). SARS-CoV-2-IN-67 inhibits SARS-CoV-2 RdRp activity .
    <em>SARS</em>-CoV-2-IN-67
  • HY-157145
    SARS-CoV-2-IN-69

    		SARS-CoV Infection
    SARS-CoV-2-IN-69 (Compound 7E) is a non-covalent SARS-CoV-2 inhibitor with an EC50 value of 7.4 μM. SARS-CoV-2-IN-69 is a potent inhibitor of SARS-CoV-2 main protease (M pro) and a non-covalent inhibitor of papain (PL pro) .
    <em>SARS</em>-CoV-2-IN-69
  • HY-163067
    SARS-CoV-2-IN-71

    		SARS-CoV Infection
    SARS-CoV-2-IN-71 (compound 8h) is a potent inhibitor of SARS-CoV-2. SARS-CoV-2-IN-71 inhibits coronavirus replication at multiple stages. SARS-CoV-2-IN-71 displays anti-coronaviral effect by simultaneously acting on 3CL pro and TMPRSS2 .
    <em>SARS</em>-CoV-2-IN-71
  • HY-146381
    SARS-CoV-2-IN-20

    		SARS-CoV Infection
    SARS-CoV-2-IN-20 (Compound 1a) is a potent inhibitor of SARS-CoV-2 with an EC50 of 6.5 μM. SARS-CoV-2-IN-20 has the potential for the research of infection diseases .
    <em>SARS</em>-CoV-2-IN-20
  • HY-135856
    SARS-CoV-IN-2
    1 Publications Verification

    		 SARS-CoV Parasite HIV Infection
    SARS-CoV-IN-2 is an effective inhibitor of SARS-CoV replication. SARS-CoV-IN-2 shows anti-Coronavirus activity with an EC50 of 1.9 μM in Vero cells. SARS-CoV-IN-2 inhibits the 3D7 and W2 strains of P. falciparum with IC50s of 21.5 and 30 nM; and IC90s of 51.0 and 99.9 nM; respectively. SARS-CoV-IN-2 reduces HIV-1-induced cytopathic effect with an EC50 of 2.9 μM in MT-4 cells. Antimalarial and Antiviral Activities .
    <em>SARS</em>-CoV-IN-2
  • HY-154975
    SARS-CoV-2-IN-49

    		SARS-CoV Others
    SARS-CoV-2-IN-49 is an irreversible covalent inhibitor of SARS-CoV-2 main protease .
    <em>SARS</em>-CoV-2-IN-49
  • HY-145276
    SARS-CoV-2-IN-10

    		SARS-CoV Infection
    SARS-CoV-2-IN-10 is a potent and nontoxic inhibitor of SARS-CoV-2 3CL protease (3CLpro) with an IC50 and EC50 of 0.13 and 1.03 nM, respectively. SARS-CoV-2 3C-like protease (3CLpro), an enzyme essential for viral replication, is an attractive target for intervention. SARS-CoV-2-IN-11 may lead to the emergence of effective SARS-CoV-2-specific antivirals .
    <em>SARS</em>-CoV-2-IN-10
  • HY-145277
    SARS-CoV-2-IN-11

    		SARS-CoV Infection
    SARS-CoV-2-IN-11 is a potent and nontoxic inhibitor of SARS-CoV-2 3CL protease (3CLpro) with an IC50 and EC50 of 0.17 and 1.45 nM, respectively. SARS-CoV-2 3C-like protease (3CLpro), an enzyme essential for viral replication, is an attractive target for intervention. SARS-CoV-2-IN-11 may lead to the emergence of effective SARS-CoV-2-specific antivirals .
    <em>SARS</em>-CoV-2-IN-11
  • HY-149315
    SARS-CoV-2-IN-48

    		SARS-CoV Infection
    SARS-CoV-2-IN-48 (compound 19) is a SARS-CoV-2 inhibitor with an IC50 of 2.7 μM for Omicron BA.1. SARS-CoV-2-IN-48 shows antiviral activities .
    <em>SARS</em>-CoV-2-IN-48
  • HY-P3492
    SARS-CoV-2-IN-34

    		SARS-CoV Infection
    SARS-CoV-2-IN-34 (S-20-1) is a blood brain barrier penetrable pan-coronavirus (CoV) fusion inhibitor with broad-spectrum inhibitory activity. SARS-CoV-2-IN-34 effectively inhibits infection by pseudotyped and authentic SARS-CoV-2, and pseudotyped variants of concern (VOCs). SARS-CoV-2-IN-34 shows high affinity to RBD in S1 and HR1 domain in S2 of SARS-CoV-2 S protein. SARS-CoV-2-IN-34 can be used for the research of infection .
    <em>SARS</em>-CoV-2-IN-34
  • HY-148387
    SARS-CoV-2-IN-35

    		SARS-CoV Infection
    SARS-CoV-2-IN-35 is a potent and orally active SARS-CoV-2 M pro inhibitor with a Ki value of 12.1 nM. SARS-CoV-2-IN-35 can be used in research of COVID-19 .
    <em>SARS</em>-CoV-2-IN-35
  • HY-149868
    SARS-CoV-2-IN-42

    		SARS-CoV Infection
    SARS-CoV-2-IN-42 (Compound 8q) is a potent inhibitor of SARS-CoV-2 replication (EC50: 0.4 μM). SARS-CoV-2-IN-42 has no obvious damage to the host cell .
    <em>SARS</em>-CoV-2-IN-42
  • HY-157144
    SARS-CoV-2-IN-68

    		SARS-CoV Infection
    SARS-CoV-2-IN-68 (compound 6C) is a covalent SARS-CoV-2 PLpro/Mpro inhibitor with potent antiviral activities. SARS-CoV-2-IN-68 binds to Zn-finger domain of PLpro .
    <em>SARS</em>-CoV-2-IN-68
  • HY-151267
    SARS-CoV-2-IN-25

    		SARS-CoV Infection
    SARS-CoV-2-IN-25 (Compound CP026) is a potent SARS-CoV-2 spike pseudoparticle transduction inhibitor with an IC50 of 1.6 μM. SARS-CoV-2-IN-25 inhibits enveloped viruses and liposomes .
    <em>SARS</em>-CoV-2-IN-25
  • HY-154976
    SARS-CoV-2-IN-50

    		SARS-CoV Infection
    SARS-CoV-2-IN-50 (Compound X77C) is a SARS-CoV-2 main protease (M Pro) inhibitor.. SARS-CoV-2-IN-50 has a high affinity to the catalytic site of M Pro .
    <em>SARS</em>-CoV-2-IN-50
  • HY-162151
    SARS-CoV-2-IN-74

    		SARS-CoV Infection
    SARS-CoV-2-IN-74 (compound 30) is a epoxide inhibitor, which inhibits cellular SARS-CoV-2 replication with an EC68 of 5 μM. SARS-CoV-2-IN-74 can be used for the research of coronavirus .
    <em>SARS</em>-CoV-2-IN-74
  • HY-139732
    SARS-CoV-2-IN-8

    		SARS-CoV Infection
    SARS-CoV-2-IN-8 is a SARS-CoV-2 main protease inhibitor with an IC50 value of 0.75 μM.
    <em>SARS</em>-CoV-2-IN-8
  • HY-139866
    SARS-CoV-2-IN-9

    		SARS-CoV Infection
    SARS-CoV-2-IN-9 is an inhibitor binding to subsites S1 and S2 in SARS-CoV-2 main protease.
    <em>SARS</em>-CoV-2-IN-9
  • HY-146157
    SARS-CoV-2-IN-22

    		SARS-CoV Infection
    SARS-CoV-2-IN-22 is a SARS-CoV-2 pseudovirus entry inhibitor with an IC50 value of 16.96 µM .
    <em>SARS</em>-CoV-2-IN-22
  • HY-149649
    SARS-CoV-2-IN-64

    		SARS-CoV Infection
    SARS-CoV-2-IN-64 (compound 9), a chenodeoxycholic acid derivative, is a potent inhibitor of spike glycoprotein of SARS-CoV-2 .
    <em>SARS</em>-CoV-2-IN-64
  • HY-162111
    SARS-CoV-2-IN-73

    		SARS-CoV Infection
    SARS-CoV-2-IN-73 (compound 4) is a SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) blocker .
    <em>SARS</em>-CoV-2-IN-73
  • HY-161261
    SARS-CoV-2-IN-81

    		AAK1 SARS-CoV Infection
    SARS-CoV-2-IN-81 (compound 12e) is a potent AAK1 inhibitor with an IC50 value of 9.38 nM. SARS-CoV-2-IN-81 shows anti-viral property against SARS-CoV-2. SARS-CoV-2-IN-81 attenuates AAK1-induced phosphorylation of AP2M1 threonine 156 and disrupts the direct interaction between AP2M1 and ACE2, ultimately inhibiting SARS-CoV-2 infection .
    <em>SARS</em>-CoV-2-IN-81
  • HY-149368
    SARS-CoV-2-IN-51

    		SARS-CoV Infection
    SARS-CoV-2-IN-51 (S-10) is a potent lead compound of Omicron fusion inhibitor. SARS-CoV-2-IN-51 inhibits Omicron and other variants with EC50s of 0.82-5.45 μM. SARS-CoV-2-IN-51 inhibits SARS-CoV-2 virus entry, by the direct interaction with S in the prefusion state .
    <em>SARS</em>-CoV-2-IN-51
  • HY-157848
    SARS-CoV-2-IN-82

    		SARS-CoV Infection
    SARS-CoV-2-IN-82 (compound A) is a Programmed-1 ribosomal frameshift (-1 PRF) inhibitor of SARS-CoV-2 .
    <em>SARS</em>-CoV-2-IN-82
  • HY-144771
    SARS-CoV-2-IN-14

    		SARS-CoV Infection
    SARS-CoV-2-IN-14 (compound 6) is a potent inhibitor of SARS-CoV-2 with an IC50 of 0.39 μM. SARS-CoV-2-IN-14 is a niclosamide analogue. SARS-CoV-2-IN-14 contains higher stability in human plasma and liver S9 enzymes assay than niclosamide, which can improve bioavailability and half-life when administered orally .
    <em>SARS</em>-CoV-2-IN-14
  • HY-144772
    SARS-CoV-2-IN-15

    		SARS-CoV Infection
    SARS-CoV-2-IN-15 (compound 11) is a potent inhibitor of SARS-CoV-2 with an IC50 of 0.49 μM. SARS-CoV-2-IN-15 is a niclosamide analogue. SARS-CoV-2-IN-15 contains higher stability in human plasma and liver S9 enzymes assay than niclosamide, which can improve bioavailability and half-life when administered orally .
    <em>SARS</em>-CoV-2-IN-15

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: